Ablynx
| Traded as | ABLX |
|---|---|
| Industry | Biotechnology |
|
Key people
|
Edwin Moses (CEO) |
| Website | www |
Edwin Moses (CEO)
Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies.
In November 2001, Ablynx was established as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). Seed financing of €2M was provided by Gimv.
In July 2015 Merck & Co. and Ablynx expanded their 18 month old immuno-oncology collaboration by four years, generating a potential $4.4 billion in milestone payments for Ablynx. In 2015, the Novo Nordisk announced it would collaborate with Ablynx, using its nanobody technology to develop at least one new drug candidate, generating a potential $400 million for the company.
...
Wikipedia